These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27756303)

  • 1. Oligomeric interface modulation causes misregulation of purine 5´-nucleotidase in relapsed leukemia.
    Hnízda A; Škerlová J; Fábry M; Pachl P; Šinalová M; Vrzal L; Man P; Novák P; Řezáčová P; Veverka V
    BMC Biol; 2016 Oct; 14(1):91. PubMed ID: 27756303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation.
    Hnízda A; Fábry M; Moriyama T; Pachl P; Kugler M; Brinsa V; Ascher DB; Carroll WL; Novák P; Žaliová M; Trka J; Řezáčová P; Yang JJ; Veverka V
    Leukemia; 2018 Jun; 32(6):1393-1403. PubMed ID: 29535428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
    Dieck CL; Tzoneva G; Forouhar F; Carpenter Z; Ambesi-Impiombato A; Sánchez-Martín M; Kirschner-Schwabe R; Lew S; Seetharaman J; Tong L; Ferrando AA
    Cancer Cell; 2018 Jul; 34(1):136-147.e6. PubMed ID: 29990496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
    Tzoneva G; Dieck CL; Oshima K; Ambesi-Impiombato A; Sánchez-Martín M; Madubata CJ; Khiabanian H; Yu J; Waanders E; Iacobucci I; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Gastier-Foster JM; Loh ML; Kirschner-Schwabe R; Mullighan CG; Rabadan R; Ferrando AA
    Nature; 2018 Jan; 553(7689):511-514. PubMed ID: 29342136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.
    Meyer JA; Wang J; Hogan LE; Yang JJ; Dandekar S; Patel JP; Tang Z; Zumbo P; Li S; Zavadil J; Levine RL; Cardozo T; Hunger SP; Raetz EA; Evans WE; Morrison DJ; Mason CE; Carroll WL
    Nat Genet; 2013 Mar; 45(3):290-4. PubMed ID: 23377183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
    Tzoneva G; Perez-Garcia A; Carpenter Z; Khiabanian H; Tosello V; Allegretta M; Paietta E; Racevskis J; Rowe JM; Tallman MS; Paganin M; Basso G; Hof J; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando A
    Nat Med; 2013 Mar; 19(3):368-71. PubMed ID: 23377281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia.
    Barz MJ; Hof J; Groeneveld-Krentz S; Loh JW; Szymansky A; Astrahantseff K; von Stackelberg A; Khiabanian H; Ferrando AA; Eckert C; Kirschner-Schwabe R
    Blood; 2020 Mar; 135(12):921-933. PubMed ID: 31971569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.
    Dieck CL; Ferrando A
    Blood; 2019 May; 133(21):2263-2268. PubMed ID: 30910786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for gene mutations: will identification of NT5C2 mutations help predict the chance of relapse in acute lymphoblastic leukemia?
    Meyer JA; Carroll WL; Bhatla T
    Expert Rev Hematol; 2013 Jun; 6(3):223-4. PubMed ID: 23782074
    [No Abstract]   [Full Text] [Related]  

  • 10. CRISPR/Cas9-Mediated Induction of Relapse-Specific
    Nguyen TTT; Tanaka Y; Sanada M; Hosaka M; Tamai M; Kagami K; Komatsu C; Somazu S; Harama D; Kasai S; Watanabe A; Akahane K; Goi K; Inukai T
    Mol Pharmacol; 2023 Apr; 103(4):199-210. PubMed ID: 36669880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric regulation and substrate activation in cytosolic nucleotidase II from Legionella pneumophila.
    Srinivasan B; Forouhar F; Shukla A; Sampangi C; Kulkarni S; Abashidze M; Seetharaman J; Lew S; Mao L; Acton TB; Xiao R; Everett JK; Montelione GT; Tong L; Balaram H
    FEBS J; 2014 Mar; 281(6):1613-1628. PubMed ID: 24456211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active and regulatory sites of cytosolic 5'-nucleotidase.
    Pesi R; Allegrini S; Careddu MG; Filoni DN; Camici M; Tozzi MG
    FEBS J; 2010 Dec; 277(23):4863-72. PubMed ID: 21029378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structures of the novel cytosolic 5'-nucleotidase IIIB explain its preference for m7GMP.
    Monecke T; Buschmann J; Neumann P; Wahle E; Ficner R
    PLoS One; 2014; 9(3):e90915. PubMed ID: 24603684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell proliferation and drug sensitivity of human glioblastoma cells are altered by the stable modulation of cytosolic 5'-nucleotidase II.
    Cividini F; Cros-Perrial E; Pesi R; Machon C; Allegrini S; Camici M; Dumontet C; Jordheim LP; Tozzi MG
    Int J Biochem Cell Biol; 2015 Aug; 65():222-9. PubMed ID: 26079827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia.
    Tulstrup M; Grosjean M; Nielsen SN; Grell K; Wolthers BO; Wegener PS; Jonsson OG; Lund B; Harila-Saari A; Abrahamsson J; Vaitkeviciene G; Pruunsild K; Toft N; Holm M; Hulegårdh E; Liestøl S; Griskevicius L; Punab M; Wang J; Carroll WL; Zhang Z; Dalgaard MD; Gupta R; Nersting J; Schmiegelow K
    Leukemia; 2018 Dec; 32(12):2527-2535. PubMed ID: 30201983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of
    Moriyama T; Liu S; Li J; Meyer J; Zhao X; Yang W; Shao Y; Heath R; Hnízda A; Carroll WL; Yang JJ
    Mol Cancer Ther; 2019 Oct; 18(10):1887-1895. PubMed ID: 31358663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia.
    Torres-Diz M; Reglero C; Falkenstein CD; Castro A; Hayer KE; Radens CM; Quesnel-Vallières M; Ang Z; Sehgal P; Li MM; Barash Y; Tasian SK; Ferrando A; Thomas-Tikhonenko A
    Cancer Res; 2024 Oct; 84(20):3327-3336. PubMed ID: 39094066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the physiological role of cytosolic 5'-nucleotidase II (cN-II): pathological and therapeutical implications.
    Tozzi MG; Pesi R; Allegrini S
    Curr Med Chem; 2013; 20(34):4285-91. PubMed ID: 23992310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of cytosolic 5'-nucleotidase II (cN-II) reveals that its activity is essential for survival in astrocytoma cells.
    Careddu MG; Allegrini S; Pesi R; Camici M; Garcia-Gil M; Tozzi MG
    Biochim Biophys Acta; 2008 Aug; 1783(8):1529-35. PubMed ID: 18445485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial studies to define the physiologic role of cN-II.
    Filoni DN; Pesi R; Careddu MG; Camici M; Allegrini S; Collavoli A; Scarfone I; Zucchi F; Galli A; Tozzi MG
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1155-60. PubMed ID: 22132970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.